Allay Therapeutics, a US-based clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, has expanded its base of operations in Singapore.

Allay has doubled its Singapore footprint with the renewal and expansion of its R&D and operations facilities in the Singapore Science Park, a leading life sciences and innovation campus. 

The company has also established its corporate headquarters in San Jose, California. Allay plans to occupy both the US site and the expanded Singapore facility by spring 2022 and complete the build-out of laboratory space in its headquarters by fall 2022.